efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
Published 2 years ago • 799 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
2:01
real-world analysis of the impact of del(17p) on ibrutinib efficacy in cll
-
2:21
outcomes of tp53-disrupted cll patients treated with frontline ibrutinib
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
1:37
causes & management of ibrutinib discontinuation in cll
-
9:34
types of immune cells part 2: myeloid and lymphoid lineages
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:06:04
itp: novel treatments
-
2:46
optimizing the combination of ibrutinib plus venetoclax in cll
-
2:42
the role of ibrutinib in dlbcl and the value of next-generation btk inhibitors
-
1:56
ibrutinib treatment and its associated risk factors
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
2:12
real-world safety and efficacy of first- and second-generation btk inhibitors in cll
-
2:24
the effectiveness of ibrutinib flexible dosing regimens on ttnt in cll/sll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
1:27
managing cardiotoxicity associated with the use of ibrutinib